Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA:688266)

SHA:688266 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,103	2,154	2,110	797.05	1,137	1,150
Trading Asset Securities	33.7	40.5	137.02	248.93	65.26	449.85
Cash & Short-Term Investments	2,137	2,194	2,247	1,046	1,202	1,600
Cash Growth	-11.53%	-2.34%	114.79%	-12.97%	-24.86%	2093.61%
Accounts Receivable	137.74	143.63	101.14	88.99	62.37	-
Other Receivables	9.62	9.38	10.89	12.51	12.45	2.62
Receivables	147.36	153.01	112.03	101.5	74.82	2.62
Inventory	167.49	182.86	110.85	98.98	51.91	23.14
Prepaid Expenses	-	-	-	-	-	0.39
Other Current Assets	45.14	45.85	50.79	45.3	77.33	43.83
Total Current Assets	2,497	2,576	2,520	1,292	1,406	1,670
Property, Plant & Equipment	351.61	363.43	271.21	247.09	188.91	91.03
Long-Term Investments	-	-	5.99	10	10	10
Other Intangible Assets	45.1	50.01	69.27	91.03	116.29	129.51
Long-Term Deferred Charges	10.23	11.39	16.39	20.96	13.03	4.35
Other Long-Term Assets	14.33	3.88	4.02	7.48	11.78	65.82
Total Assets	2,918	3,005	2,887	1,668	1,746	1,970
Accounts Payable	201.59	197.1	137.73	151.72	118.19	64.96
Accrued Expenses	46.44	68.5	74.96	67.5	48.22	30.92
Short-Term Debt	881.53	951.86	795.16	390.79	131.81	17.67
Current Portion of Long-Term Debt	49.94	16.17	50.56	50.04	30.03	-
Current Portion of Leases	-	-	13.17	13.69	13.55	-
Current Income Taxes Payable	36.62	33.45	20.64	20.29	18.58	16.94
Current Unearned Revenue	0.27	-	-	0.28	0.36	-
Other Current Liabilities	109.08	106.36	42.95	34.88	20.16	10.38
Total Current Liabilities	1,325	1,373	1,135	729.19	380.89	140.88
Long-Term Debt	59.81	44.35	-	50.09	-	30.03
Long-Term Leases	13.07	26.86	29.46	43.18	48.18	4.32
Long-Term Unearned Revenue	8.02	9.2	11.55	45.04	48.05	83.66
Long-Term Deferred Tax Liabilities	4.69	5.7	9.58	13.32	15.77	19.81
Other Long-Term Liabilities	283.02	292.45	56.6	-	-	-
Total Liabilities	1,694	1,752	1,242	880.82	492.88	278.69
Common Stock	264.71	264.71	264.71	240	240	240
Additional Paid-In Capital	3,121	3,120	3,353	2,222	2,205	2,174
Retained Earnings	-2,145	-2,117	-1,979	-1,700	-1,243	-791.56
Comprehensive Income & Other	-14.34	-14.47	-5.95	-2.84	-6.32	-5.04
Total Common Equity	1,226	1,254	1,633	759.12	1,196	1,618
Minority Interest	-2.28	-1.26	11.98	28.37	56.76	73.86
Shareholders' Equity	1,224	1,253	1,645	787.49	1,253	1,692
Total Liabilities & Equity	2,918	3,005	2,887	1,668	1,746	1,970
Total Debt	1,004	1,039	888.35	547.8	223.57	52.02
Net Cash (Debt)	1,132	1,155	1,358	498.18	978.32	1,548
Net Cash Growth	-20.05%	-14.97%	172.65%	-49.08%	-36.78%	19021.89%
Net Cash Per Share	4.30	4.36	5.31	2.08	4.08	6.59
Filing Date Shares Outstanding	256.93	264.71	264.71	264.49	240	240
Total Common Shares Outstanding	256.93	264.71	264.71	240	240	240
Working Capital	1,171	1,202	1,385	562.57	1,025	1,529
Book Value Per Share	4.77	4.74	6.17	3.16	4.98	6.74
Tangible Book Value	1,181	1,204	1,564	668.09	1,080	1,488
Tangible Book Value Per Share	4.60	4.55	5.91	2.78	4.50	6.20
Buildings	-	-	41.93	41.93	41.21	-
Machinery	-	-	125.42	121.74	96.02	-
Construction In Progress	-	-	135.83	86.67	27.25	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.